Rising Pharmaceuticals Admits Price Fixing

New Jersey-based generic drugmaker Rising Pharmaceuticals admitted to price fixing for the hypertension drug Benazepril HCTZ and agreed to pay more than $3 million under a deferred prosecution agreement with the Department of Justice.

The DOJ previously entered into a deferred prosecution agreement with Heritage Pharmaceuticals.

The department will hold off on prosecuting Rising for three years, or until the company’s  bankruptcy proceedings are completed.